Published in Clin Rev Allergy Immunol on December 01, 2011
On the role of skin in the regulation of local and systemic steroidogenic activities. Steroids (2015) 1.01
Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal α-toxin-induced keratinocyte death. J Allergy Clin Immunol (2012) 0.94
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol (2011) 0.94
Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function. J Invest Dermatol (2012) 0.90
Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol (2014) 0.87
Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol (2014) 0.85
Lipid abnormalities and lipid-based repair strategies in atopic dermatitis. Biochim Biophys Acta (2013) 0.82
Role of the steroidogenic acute regulatory protein in health and disease. Endocrine (2015) 0.81
Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol (2014) 0.80
Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol (2014) 0.76
Prevention of atopic dermatitis. F1000 Med Rep (2012) 0.76
Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis. J Vet Sci (2012) 0.76
Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol (2016) 0.75
Local rhamnosoft, ceramides and L-isoleucine in atopic eczema: a randomized, placebo controlled trial. Pediatr Allergy Immunol (2014) 0.75
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 9.01
Atopic dermatitis. N Engl J Med (2008) 5.92
The development of allergic inflammation. Nature (2008) 4.52
Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol (2003) 3.41
Stratum corneum defensive functions: an integrated view. J Invest Dermatol (2005) 3.20
A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet (2009) 2.96
Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol (2007) 2.79
Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol (1991) 2.52
Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol (2009) 2.43
The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem (1995) 2.39
IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol (2006) 2.39
Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol (2001) 2.34
Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol (2008) 2.20
Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol (2006) 2.17
Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol (2006) 2.16
Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol (2008) 2.11
New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol (2006) 2.06
Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol (2007) 2.04
Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol (2007) 2.02
Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol (2004) 1.97
Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol (2002) 1.94
Histidine-rich proteins (filaggrins): structural and functional heterogeneity during epidermal differentiation. J Mol Biol (1983) 1.94
Filaggrin in atopic dermatitis. J Allergy Clin Immunol (2008) 1.89
Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest (1993) 1.87
Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med (2009) 1.83
The skin barrier as an innate immune element. Semin Immunopathol (2007) 1.81
pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol (2003) 1.75
Filaggrin breakdown to water binding compounds during development of the rat stratum corneum is controlled by the water activity of the environment. Dev Biol (1986) 1.71
The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol (2003) 1.67
Gene polymorphism in Netherton and common atopic disease. Nat Genet (2001) 1.66
"Outside-to-inside" (and now back to "outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol (2008) 1.64
Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol (1985) 1.59
A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol (2005) 1.58
Filaggrin's fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol (2007) 1.57
Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol (1998) 1.56
Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol (2009) 1.52
Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol (2005) 1.51
Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol (2006) 1.51
Skin barrier function and allergic risk. Nat Genet (2006) 1.50
Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol (2005) 1.48
Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol (2003) 1.47
Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci (2006) 1.47
Stratum corneum moisturization at the molecular level. J Invest Dermatol (1994) 1.44
Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med (2008) 1.43
Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol (2009) 1.43
Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol (2007) 1.41
Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics (2005) 1.39
Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta (1982) 1.34
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol (2006) 1.33
In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol (2003) 1.33
The role of microorganisms in atopic dermatitis. Clin Exp Immunol (2006) 1.31
In vivo studies concerning a pH gradient in human stratum corneum and upper epidermis. Acta Derm Venereol (1994) 1.28
Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation (1998) 1.28
Objective assessment of the skin of children affected by atopic dermatitis: a study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol (1995) 1.25
The characterization of human epidermal filaggrin. A histidine-rich, keratin filament-aggregating protein. Biochim Biophys Acta (1983) 1.25
Antimicrobial activity of sphingosines. J Invest Dermatol (1992) 1.24
Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol (2003) 1.23
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22
Superantigen profile of Staphylococcus aureus isolates from patients with steroid-resistant atopic dermatitis. Clin Infect Dis (2008) 1.22
Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat (1999) 1.20
Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the protease-activated receptor type 2. Am J Pathol (2007) 1.20
Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol (2001) 1.19
Glucocorticoid blockade reverses psychological stress-induced abnormalities in epidermal structure and function. Am J Physiol Regul Integr Comp Physiol (2006) 1.19
Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum -an unexpected role for urocanic acid. J Invest Dermatol (2000) 1.19
Stratum corneum acidification is impaired in moderately aged human and murine skin. J Invest Dermatol (2007) 1.18
In vitro and in vivo antistaphylococcal activity of human stratum corneum lipids. Arch Dermatol (1988) 1.18
Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol (2003) 1.17
The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol (2001) 1.16
Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol (2005) 1.15
Epidermal keratinocytes as the forefront of the sensory system. Exp Dermatol (2007) 1.13
Filaggrin expression in oral, nasal, and esophageal mucosa. J Invest Dermatol (2008) 1.12
Hypothesis: from epidermal barrier dysfunction to atopic disorders. Contact Dermatitis (1999) 1.09
Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol (2006) 1.08
Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure. J Pediatr (2004) 1.07
Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort. Acta Derm Venereol (2007) 1.06
Maintenance of an acidic stratum corneum prevents emergence of murine atopic dermatitis. J Invest Dermatol (2009) 1.04
Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol (2009) 1.04
Staphylococcus aureus clonal dynamics and virulence factors in children with atopic dermatitis. J Invest Dermatol (2005) 1.04
Genetic association between an AACC insertion in the 3'UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol (2004) 1.03
Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes. J Invest Dermatol (1985) 1.03
The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology (2007) 1.02
IL-1 beta activation in human epidermis. J Immunol (1996) 1.01
IL-4 suppresses the recovery of cutaneous permeability barrier functions in vivo. J Invest Dermatol (2007) 1.01
Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Exp Dermatol (1996) 0.99
Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol (2001) 0.98
Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol (2009) 0.97
Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. J Allergy Clin Immunol (2008) 0.96
Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol (2009) 0.96
A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol (2001) 0.95
Staphylococcus aureus enterotoxins induce histamine and leukotriene release in patients with atopic eczema. Br J Dermatol (2001) 0.95
Black box warning for topical calcineurin inhibitors and the death of common sense. Dermatol Online J (2006) 0.92
Absence of the granular layer and keratohyalin define a morphologically distinct subset of individuals with ichthyosis vulgaris. Exp Dermatol (2002) 0.91
Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. Am J Clin Dermatol (2009) 0.89
Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol (2005) 0.88
Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol (2008) 0.87
Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics (2008) 0.87
LEKTI-1 in sickness and in health. Int J Cosmet Sci (2009) 0.86
Potential new indications of topical calcineurin inhibitors. Dermatology (2007) 0.86
Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function. Exp Dermatol (2009) 0.84
Unexpected high serum levels of tacrolimus after a single topical application in an infant. J Pediatr (2003) 0.84